Daniel Fabricant, Director of the Food and Drug Administration’s (FDA) Division of Dietary Supplement Programs, recently told attendees of the American Herbal Products Association’s (AHPA) inaugural Botanical Congress in New York that industry companies can expect more inspections, more injunctions, and more product seizures from FDA related to current good manufacturing practice (cGMP) violations.